May 16, 2025

FDA Clears First Blood Test for Alzheimer’s

The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.

Conexiant

May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant

May 16, 2025

Novel Prediction Model for Hearing Loss From Chemotherapy in Pediatric Patients With Cancer

In a study reported in the Journal of Clinical Oncology, Millstein et al attempted to develop a predictive model—Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR)—for hearing loss associated w...

The ASCO Post

May 16, 2025

3 things you missed in government this week

ADA News is providing a roundup of happenings in government you may have missed.

ADA News

May 16, 2025

vNOTES Speeds Bowel, Work Recovery After Hysterectomy

A prospective study found that patients who underwent vNOTES hysterectomy recovered bowel function and returned to work faster than those who had traditional laparoscopic surgery.

Conexiant

May 16, 2025

Neoadjuvant Therapy for IBD-Related Rectal Cancer

Total neoadjuvant therapy was shown to be less effective for treating patients with rectal cancer with inflammatory bowel disease (IBD) than those with sporadic rectal cancer, according to study findi...

The ASCO Post

May 16, 2025

Second-Line Endocrine Therapy With/Without Palbociclib Rechallenge in HR-Positive, HER2-Negative Advanced Breast Cancer

In a phase II trial (PALMIRA) reported in the Journal of Clinical Oncology, Llombart-Cussac et al evaluated whether palbociclib rechallenge with second-line alternative endocrine therapy improved prog...

The ASCO Post

May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 16, 2025

Laboratory Developed Tests: Did We Really Win?

Rethinking the overturn of the FDA’s LDT rule

The Pathologist